ArticleThe world journal of men's health2013
Treatment Strategy for Non-Responders to PDE5 Inhibitors.
Article in The world journal of men's health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction.Journal of Korean medical science · 2017Trial
- Apparent Non-Response to Phosphodiesterase Type 5 Inhibitors in Erectile Dysfunction: A Narrative Review of Structured Reassessment and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Intracavernous Injection Therapy as Second-Line Treatment for ED After Radical Prostatectomy: A Literature Review.Medicina (Kaunas, Lithuania) · 2026Review
- Identification of Emotional Spectrums of Patients Taking an Erectile Dysfunction Medication: Ontology-Based Emotion Analysis of Patient Medication Reviews on Social Media.Journal of medical Internet research · 2023Article
- Canadian Urological Association guideline: Erectile dysfunction.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Development of a novel topical formulation of glyceryl trinitrate for the treatment of erectile dysfunction.International journal of impotence research · 2020Review
- Serum L-carnitine and vitamin D levels may be low among oral sildenafil citrate non-responders.International journal of impotence research · 2019Article
- The effect of low-intensity extracorporeal shockwave therapy in an obesity-associated erectile dysfunction rat model.BJU international · 2018Article
- Drug-related problems in patients with erectile dysfunctions and multiple comorbidities.Therapeutics and clinical risk management · 2017Article
- Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience.Therapeutic advances in urology · 2016Review
- Erectile dysfunction: a window to the heart.BMJ case reports · 2015Article
- The prescribing and dispensing of phosphodiesterase type 5 inhibitors in South Korea: a questionnaire survey of patient discomfort.The world journal of men's health · 2014Article
- Role of Schwann cells in the regeneration of penile and peripheral nerves.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.